Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells

Journal of Immunology

Volumn 156, Issue 10, 1996, Pages 3875-3881

  Ohno, Koichiro ^a   Yoshizawa, Hirohisa ^a   Tsukada, Hiroko ^a   Takeda, Tetsuro ^a   Yamaguchi, Yoshifumi ^a   Ichikawa, Kentaro ^a   Maruyama, Yoshie ^a   Suzuki, Yoshiyuki ^a   Suzuki, Eiichi ^a   Arakawa, Masaaki ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY CD3;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FIBROSARCOMA; LUNG METASTASIS; LYMPH NODE CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROLYMPHOCYTE; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD3; CELL DIVISION; CYTOKINES; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 9244254725     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rosenberg, S. A., and W. D. Terry. 1977. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25:323.
2. Smith, H. G., R. P. Harmel, M. G. Hanna Jr., B. S. Zwilling, B. Zbar, and H J Rapp. 1977. Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. J. Natl. Cancer Inst. 58:1315.
3. Fernandez-Cruz, E., B. Halliburton, and J D. Feldman. 1979. In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma. J. Immunol. 123:1772.
4. Cheever, M. A., P. D. Greenberg, and A. Fefer. 1984. Potential for specific cancer therapy with immune T lymphocytes. J. Biol. Response Mod. 3:113.
5. Shu, S., and S. A. Rosenberg. 1985. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J. Immunol. 135:289-5.
6. Yoshizawa, H., K. Sakai, A. E. Chang, and S. Shu. 1991. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy Cell. Immunol. 134:473.
7. Yoshizawa, H., A. E. Chang, and S. Shu 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and DL-2. J. Immunol. 147:729.
8. Yoshizawa, H., K. Sakai, A. E. Chang, and S. Shu 1992. Cellular interactions in effector generation and and tumor regression mediated by anti-CD3/interleukin 2 activated tumor-draining lymph node cells. Cancer Res. 52:1129.
9. Mitsuma, S., H. Yoshizawa, K. Ito, H. Monyama, M Wakabayashi, T. Chou, M. Arakawa, and S. Shu. 1994 Adoptive immunotherapy mediated by anti-TCR/ IL-2-activated tumour-draining lymph node cells. Immunology 83:45.
10. Miyao, H., T. Chou, K. Ito, H. Moriyama, S. Mitsuma, M. Wakabayashi, H. Yoshizawa, and M. Arakawa. 1994. Treatment of advanced primary lung cancer associated with malignant pleural effusion by the combination of immunotherapy and chemotherapy. Oncology 51:87.
11. Ito, K., T. Chou, S. Mitsuma, H. Moriyama, M. Wakabayashi, A. Mizusawa, H. Miyao, H. Yoshizawa, T. Tsuchiya, T. Ebe, L. Yuejing, and M. Arakawa. 1993. A novel chemo-immunotherapy for advanced non-small cell lung cancer. J. Jpn. Soc. Cancer Ther. 29:36.
12. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H I. Levitsky, J. W Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397.
13. Tsai, S. C , B. Gansbacher, L. Tait, F. R. Miller, and G. H. Heppner. 1993 Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl Cancer Inst. 85:546.
14. Ohe, Y., E. R. Podack, K J. Olsen, Y. Miyahara, T. Ohira, K. Miura, K Nishio, and N. Saijo. 1993. Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int. J. Cancer 53.432.
15. Tepper, R. I., P. K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
16. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4 Science 254:713.
17. Okada, M., M. Kitahara, S. Kishimoto, T. Matsuda, T. Hirano, and T. Kishimoto. 1988. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 141:1543.
18. Porgador, A., E. Tzehoval, A. Katz, E. Vadai, M. Revel, M. Feldman, and L. Eisenbach. 1992 Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52:3679.
19. Gansbacher, B., R. Bannerji, B. Daniels, K. Zier, K Cronin, and E. Gilboa. 1990. Retroviral vector-mediated γ-interferon gene transfer into rumor cells generates potent and long lasting antitumor immunity Cancer Res. 50:7820
20. Nishihara, K , S. Miyatake, T Sakata, J. Yamashita, H. Kikuchi, Y. Kawade, Y Zu, Y. Namba, M Hanaoka, and Y. Watanabe. 1988. Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse γ-interferon complementary DNA Cancer Res. 48: 4730.
21. Watanabe, Y , K. Kuribayashi, S. Miyatake, K Nishihara, E. Nokayama, T. Taniyama, and T. Sakata 1989. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86:9456.
22. Asher, A. L., J J. Mule, A Kasid, N. P. Restifo, J C. Salo, C M. Reichert, G. Jaffe, B. Fendly, M. Kriegler, and S. A. Rosenberg. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-α: evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146:3227.
23. Karp, S. E., A. Farber, J. C. Salo, P. Hwu, G. Jaffe, A. L. Asher, E. Shiloni, N. P. Restifo, J. J. Mule, and S. A. Rosenberg. 1993. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: tumor inhibition by IL-2 but not tumor necrosis factor J. Immunol. 150:896.
24. Vanhaesebroeck, B., M. Mareel, F. Van Roy, J. Grooten, and W. Fiers. 1991. Expression of the tumor necrosis factor gene in tumor cells correlates with reduced tumorigenicity and reduced invasiveness in vivo. Cancer Res. 51:2229.
25. Colombo, M. P., G. Ferrari, A. Stoppacciaro, M. Parenza, M. Rodolfo, F. Mavilio, and G Parmiani. 1991. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173:889.
26. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
27. Karasuyama, H., and F. Melchers. 1988 Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur. J. Immunol 18:97.
28. Wexler, H. 1966. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst. 36:641.
29. Shu, S., R. A. Krinock, T Matsumura, J. J. Sussman, B. A. Fox, A. E. Chang, and D. S. Terman. 1994. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J. Immunol. 152.1277.
30. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.
31. Topalian, S. L., D. Solomon, F. P. Avis, A. E. Chang, D. L. Freerksen, W. M. Linehan, M T. Lotze, C. N. Robertson, C A. Seipp, P. Simon, et al. 1988. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:839.
32. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S L. Topalian, S. T. Toy, P. Simon. M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic mekanoma: a preliminary report. N. Engl. J Med. 319:1676.
33. Chang, A. E., H. Yoshizawa, K. Sakai, M. J. Cameron, V. K. Sondak, and S. Shu. 1993 Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 53:1043.
34. Treves, A J., C. Carnaud, N. Trainin, M Feldman, and I. R Cohen. 1974. Enhancing T lymphocytes from tumor-bearing mice suppress host resistance to a syngeneic tumor. Eur J. Immunol. 4:722.
35. Dye, E. S., and R. J North. 1981. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocyloma and its metastases. J. Exp. Med. 154:1033
36. Sondak, V. K., P. D Wagner, S. Shu, and A. E. Chang. 1991. Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch. Surg 126:442.
37. Hellström, K. E., and I. Hellström 1974. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv. Immunol 18:209.
38. Tada, T., S Ohzeki, K. Utsumi, H. Takiuchi, M. Muramatsu, X. F. Li, J. Shimizu, H. Fujiwara, and T Hamaoka. 1991. Transforming growth factor-β-mduced inhibition of T cell function: susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol 146:1077.
39. + T cell activity. J. Immunol. 148.648.
40. + T cell function. Jpn. J. Cancer Res. 84.315.